TELIX Pharmaceuticals Ltd (TLX) — Cash Flow Reinvestment Rate
TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow Reinvestment Rate of 0.36x as of June 2025, reinvesting AU$10.13 Million (capex AU$10.13 Million ) from operating cash flow of AU$27.98 Million. See TELIX Pharmaceuticals Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
TELIX Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for TELIX Pharmaceuticals Ltd across 3 annual periods. For the full cash flow conversion analysis, see cash flow conversion of TELIX Pharmaceuticals Ltd.
Annual Cash Flow Reinvestment Rate for TELIX Pharmaceuticals Ltd (2020–2024)
Year-by-year capital reinvestment analysis for TELIX Pharmaceuticals Ltd. See TLX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (AUD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 3.93x | AU$169.21 Million | AU$43.03 Million | AU$34.03 Million | ▲ +158.9% |
| 2023 | 1.52x | AU$36.28 Million | AU$23.88 Million | AU$10.79 Million | ▲ +110.7% |
| 2020 | 0.72x | AU$1.41 Million | AU$1.96 Million | AU$322.00K | — |